Board of Directors
Nick Rodgers, Chairman
Nick Rodgers has considerable Board experience in both public and private growth companies, particularly those in the life science sector, as well as a background as a successful corporate financier and investment banker. Nick is currently chairman of SEHTA, one of the largest health technology networking organisations in the UK. Prior to this, he was non-executive director and then chairman of fully listed Oxford Biomedica plc, a leading gene-based biopharmaceutical company, from 2004 until 2016. Previously. Nick headed up both the Life Science and Corporate Finance department at Evolution Beeson Gregory (now Investec) advising many listed life science companies from 1989 until 2003.
Nick was appointed as a Non-executive Director of the Company in June 2018.
Neil Clark, Chief Executive Officer
Neil qualified as an accountant with PWC in Cambridge, UK and worked for over ten years on a variety of local, national and international assignments in audit, corporate finance and consultancy.
In 1997, Neil joined CeNeS Pharmaceuticals plc, a venture capital backed private UK biotech company. He was involved in the flotation of CeNeS in 1999 in London and appointed CFO. In 2001 he became COO as well as CFO, overseeing a restructuring of the business. He became CEO in 2005 and led the company through to its sale in 2008. At CeNeS he was involved in several licensing deals, fund raisings and corporate transactions including the acquisition and disposal of several businesses.
Neil joined Ergomed as Chief Finance Officer in January 2009 and was CFO on its IPO in July 2014 until his move to be full time CEO of PrimeVigilance (Ergomed’s successful drug safety business) in January 2016 having been closely involved in the management of PrimeVigilance since its formation in 2009.
Neil has been working with Destiny Pharma on a consultancy basis since September 2016 and was appointed to the Board in January 2017. Neil is a Fellow of the Institute of Chartered Accountants in England and Wales and has a BSc in Bioscience from the University of Nottingham.
Dr William Love, Founder and Chief Scientific Officer
Bill was a Senior Scientist at Ciba Geigy/Novartis focused on novel Drug Delivery technologies and involved in development of the world’s leading eye-care pharmaceutical, Visudyne. In 1997, Bill founded Destiny Pharma and he is the co-inventor of the XF drug platform.
Bill was a founding member of the BEAM Alliance, an EU SME group focused on promoting anti-microbial drug development. He is an Expert Advisory Board member of Global AMR Innovation Fund, appointed by Professor Dame Sally Davies in October 2016. Bill is the named inventor in more than 70 patents. He has experience in drug R&D from Discovery and Lead identification, through Pre-clinical development and into Phase I/II Clinical development in the UK, EU and US.
Shaun Claydon, Chief Financial Officer
Shaun is an accomplished corporate financier and qualified Chartered Accountant with over 16 years board level experience, including within the biotechnology sector. He has extensive experience of delivering financial and operating results and from 2015 served as CFO of Creabilis, a venture backed clinical stage specialty pharmaceutical company focused on dermatology treatments, during which he led a $150 million sale of the business to Sienna Biopharmaceuticals.
From 2009 to 2014 Shaun was CFO and Chief Operating Officer of Orteq Sports Medicine, a medical device company and world leader in the field of biodegradable polymer technologies.
Prior to these positions he spent over 10 years as a corporate financier and Nominated Adviser advising private and public clients on a wide range of UK and international corporate transactions. He has held a number of senior financial consultancy and corporate finance roles including at PwC, BDO, Evolution Securities and HSBC, the latter where he was responsible for origination and execution of domestic and international mergers as a director in HSBC’s Investment Banking division.
Shaun is a member of the Institute of Chartered Accountants in England and Wales and holds a BA in Economics from the University of Leeds.
Joe Eagle, Non-executive Director
Joe’s early career was spent in product management and business development in the Wellcome Group, Pfizer and Ciba-Geigy in locations including London, Brussels, Nairobi and Hong Kong, culminating as Marketing Director at Ciba-Geigy Pharmaceuticals UK between 1981 and 1986.
In 1986, he set up PPS Europe Limited, an international pre-launch medical education and publishing services provider to the Pharmaceutical industry, acting as Chairman and Chief Executive Officer. PPS Europe Ltd was sold to Parexel US in 1999, following which, Joe took the position of President of Medical Marketing Services for 2 years at Parexel and served as a Board Director of Parexel International.
In 2002, Joe founded Road Angel Group, a consumer electronics business of which he was executive chairman through its sale in 2006.
Since 2008, Joe has been an angel investor in SMEs in various sectors. Joe has a BSc in Physiology and Biochemistry from the University of Southampton. He has been a Director of the Company since June 2002.
While Joe is a shareholder and option holder in the Company and has served on the Board for some years, based on his extensive experience, specialised industry knowledge and personal qualities, the Board consider him to be independent.
Peter Morgan, Non-executive Director
Peter’s early career was spent in the pharmaceutical industry, initially in engineering and technical operations and then sales and marketing. He was a product manager in UK pharma industry before moving to become managing director of a Ciba-Geigy (now Novartis) subsidiary in Scandinavia.
In 1987, Peter became a founder Director of Beaufort Group Limited, a business services company which provided advice and support to pharmaceutical companies and the newly privatised utilities, which was admitted to AIM in 1996. Peter stepped down from Beaufort in 1998 to focus on a portfolio of consulting and investment opportunities. From 2007 until 2015, Peter was a non-executive director of Oncimmune Limited, a cancer diagnostics company spin out from Nottingham University which floated on AIM in 2016.
Peter has advised many of the world’s top pharmaceutical companies including Amgen, Bayer, GSK, Novartis, Novo Nordisk, Pfizer and Roche as well as Quintiles, the world’s largest clinical research organisation. He has a BSc from Nottingham University and an MBA from London Business School.
While Peter is a shareholder and option holder in the Company and has served on the Board for some years, based on his extensive experience, specialised industry knowledge and personal qualities, the Board consider him to be independent.
Peter’s engagement with the Company commenced on 3 April 2000.
Dr Huaizheng Peng, Non-executive Director
Huaizheng serves as General Manager of International Operations for China Medical System Holdings, a specialty pharmaceutical company listed on the Hong Kong Stock Exchange. He is in charge of international operations for the Company, including pharmaceutical asset acquisition/product licensing-in/out, international business development, outbound investment and asset management, among others. Huaizheng served as an independent Non-executive Director of China Medical System Holdings Ltd for three years, and that company was admitted to trading on AIM (between 2007 and 2010).
Huaizheng was a partner of Northland Bancorp, a private equity firm. Before that, he worked as a head of life sciences and as a director of corporate finance at Seymour Pierce, a London-based investment bank and stockbroker. In addition, he was a Non-executive Director of China Medstar, an AIM listed medical device company. Earlier in his career Huaizheng was a senior portfolio manager, specialising in global life science and Asian technology investment at Reabourne Technology Investment Management Limited.
Huaizheng received his Bachelor´s degree in medicine from Hunan Medical College (now Central South University Xiangya School of Medicine) in Changsha, Hunan Province, China and he subsequently obtained a Master´s degree in medicine from Hunan Medical College. Huaizheng was awarded his PhD in molecular pathology from University College London (UCL) Medical School, London, UK and subsequently practiced as a clinical lecturer there.
Huaizheng was appointed as a Non-executive Director of the Company in November 2017.